Expression and secretion of icil-1 receptor antagonist type ii
CA 2344711 A1 · Owner: Applied Research Systems Ars Holding N.V. · Inventors: Chitlaru, Edith; Amitai, Hagit
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel glycosylated intracellular IL-1 receptor antagonist type II (icIL-1ra- II) is expressed and secreted in mammalian cells transformed with an expression vector where icIL-1ra-II is secreted by expressing icIL-1ra-II fused to the human growth hormone signal peptide. Also disclosed are a pharmaceutical composition containing glycosylated icIL-1ra-II as an active ingredient and a method for reducing IL-1 levels in patients having a condition involving overexpressed IL-1.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 14, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 14, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 14, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.